DNA 시퀀싱 시장 : 제품 및 서비스, 기술, 워크플로우, 용도별 - 세계 예측(2025-2030년)

The DNA Sequencing Market was valued at USD 60.39 billion in 2023, expected to reach USD 71.98 billion in 2024, and is projected to grow at a CAGR of 19.51%, to USD 210.34 billion by 2030.

DNA sequencing is a cutting-edge technology pivotal in multiple sectors, primarily healthcare, biotechnology, agriculture, and forensic sciences. The scope of DNA sequencing encompasses vast applications such as genomic research, disease diagnosis, personalized medicine, and genetic engineering. In healthcare, it is a crucial tool for early detection and treatment of genetic disorders, cancer, and infectious diseases through precise genomic insights. Agriculture benefits from DNA sequencing by improving crop resilience and productivity while forensics utilizes it for identity verification and criminal investigations. Key factors driving market growth include advancements in sequencing technologies, declining sequencing costs, and surged governmental and private investment in genomics research. Additionally, the rising prevalence of chronic diseases necessitates robust diagnostic solutions, with DNA sequencing at the forefront due to its precision and reliability. However, market growth faces limitations such as ethical concerns, stringent regulatory frameworks, and data privacy issues. The complexity of data interpretation and lack of skilled professionals further complicate the landscape. Nevertheless, opportunities abound in developing portable sequencing devices, automated data analysis solutions, and cloud-based platforms for data storage and sharing. Companies are also poised to expand in emerging economies due to untapped potential and increased healthcare infrastructure investments. Innovation could focus on enhancing sequencing speed and accuracy, integrating AI for better data analytics, and ensuring cost-efficiency to widen accessibility and adoption. The DNA sequencing market is inherently dynamic, driven by continuous technological advancements and evolving regulatory landscapes. Staying competitive demands strategic partnerships, investment in R&D, and adherence to emerging ethical guidelines. With precision medicine gaining traction, embracing machine learning for predictive analytics, and exploring synthetic biology could pave the way for groundbreaking applications and market expansions. Consequently, the market remains promising yet challenging, with a clear path to growth for those who can balance innovation with ethical practices and regulatory compliance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving DNA Sequencing Market

The DNA Sequencing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing cases of genetic disorders across the world
  • Increasing role of NGS in companion diagnostics and personalized medicines
  • Growing usage of DNA sequencing across agrigenomics and forensics
• Market Restraints
  • Technical limitations associated with DNA sequencing
• Market Opportunities
  • Advancements and developments in DNA sequencing
  • Rising investments in DNA sequencing and single-cell sequencing
• Market Challenges
  • Issues associated with the accuracy, reliability, and ethical implications of DNA sequencing

Porter's Five Forces: A Strategic Tool for Navigating the DNA Sequencing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the DNA Sequencing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the DNA Sequencing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the DNA Sequencing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the DNA Sequencing Market

A detailed market share analysis in the DNA Sequencing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the DNA Sequencing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the DNA Sequencing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the DNA Sequencing Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, Inc., Abbott Laboratories, AbbVie Inc., Agilent Technologies, Inc., Azenta, Inc., Becton, Dickinson and Company, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., BioChain Institute Inc., Charles River Laboratories International, Inc., Danaher Corporation, Dante Labs Inc., Eppendorf SE, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Genomics England, Genscript Biotech Corporation, Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Laboratory Corporation of America Holdings, Macrogen Inc., Merck KGaA, Novartis AG, Novogene Co, Ltd., Oxford Nanopore Technologies PLC, Pacific Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN N.V., Sartorius AG, Shimadzu Corporation, SOPHiA GENETICS SA, Thermo Fisher Scientific Inc., Twist Bioscience Corporation, and Veritas Genetics Inc. by LetsGetChecked.

Market Segmentation & Coverage

This research report categorizes the DNA Sequencing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product & Services, market is studied across Consumables, Instruments, and Services.
• Based on Technology, market is studied across Next-Generation Sequencing, Sanger Sequencing, and Third Generation DNA Sequencing. The Next-Generation Sequencing is further studied across Targeted Sequencing & Resequencing, Whole Exome Sequencing, and Whole Genome Sequencing. The Third Generation DNA Sequencing is further studied across Nanopore Sequencing and Single-Molecule Real-Time Sequencing.
• Based on Workflow, market is studied across Data Analysis, Pre-Sequencing, and Sequencing.
• Based on Application, market is studied across Agrigenomics & Forensics, Clinical Investigation, Consumer Genomics, HLA Typing or Immune System Monitoring, Metagenomics, Epidemiology & Drug Development, Oncology, and Reproductive Health.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing cases of genetic disorders across the world
    • 5.1.1.2. Increasing role of NGS in companion diagnostics and personalized medicines
    • 5.1.1.3. Growing usage of DNA sequencing across agrigenomics and forensics
  • 5.1.2. Restraints
    • 5.1.2.1. Technical limitations associated with DNA sequencing
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements and developments in DNA sequencing
    • 5.1.3.2. Rising investments in DNA sequencing and single-cell sequencing
  • 5.1.4. Challenges
    • 5.1.4.1. Issues associated with the accuracy, reliability, and ethical implications of DNA sequencing
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product & Services: Evolution across services with advances in bioinformatics and computational biology
  • 5.2.2. Technology: Growing popularity of next-generation sequencing (NGS) for ultra-high throughput
  • 5.2.3. Workflow: Rising preference for sequencing methods to meet accuracy requirements
  • 5.2.4. Application: Expanding application of DNA sequencing in clinical investigation for precise diagnosis and understanding of genetic disorders
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. DNA Sequencing Market, by Product & Services

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Instruments
• 6.4. Services

7. DNA Sequencing Market, by Technology

• 7.1. Introduction
• 7.2. Next-Generation Sequencing
  • 7.2.1. Targeted Sequencing & Resequencing
  • 7.2.2. Whole Exome Sequencing
  • 7.2.3. Whole Genome Sequencing
• 7.3. Sanger Sequencing
• 7.4. Third Generation DNA Sequencing
  • 7.4.1. Nanopore Sequencing
  • 7.4.2. Single-Molecule Real-Time Sequencing

8. DNA Sequencing Market, by Workflow

• 8.1. Introduction
• 8.2. Data Analysis
• 8.3. Pre-Sequencing
• 8.4. Sequencing

9. DNA Sequencing Market, by Application

• 9.1. Introduction
• 9.2. Agrigenomics & Forensics
• 9.3. Clinical Investigation
• 9.4. Consumer Genomics
• 9.5. HLA Typing or Immune System Monitoring
• 9.6. Metagenomics, Epidemiology & Drug Development
• 9.7. Oncology
• 9.8. Reproductive Health

10. Americas DNA Sequencing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific DNA Sequencing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa DNA Sequencing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Ultima Genomics Launching High-end DNA Sequencers that can Read Genome for USD 100
  • 13.3.2. GBP 46.3 Million Funding Boost to Shine Light on Dark Genome
  • 13.3.3. BD, Hamilton Collaborate to Standardize Single-Cell Multiomics Experiments Using Robotics
  • 13.3.4. Oxford Nanopore Announces Performance in Simplex Single Molecule Accuracy to Provide Comprehensive Genomic Data for Diverse Customer Types
  • 13.3.5. Element Biosciences Inc. and Agilent Technologies Expand Partnership to Expand Product Portfolio
  • 13.3.6. Alliance Hopes to Automate Nanopore Library Preparation to Revolutionize the DNA Sequencing
  • 13.3.7. Tecan and Oxford Nanopore partnered for Long Fragment DNA Sequencing
  • 13.3.8. UPS Healthcare & Oxford Nanopore partner to deliver DNA sequencing tech across APAC
  • 13.3.9. NIH Software Assembles Complete Genome Sequences On-demand
  • 13.3.10. Eurofins Genomics US Launches Express Oxford Nanopore Sequencing Service with Same-Day Results
  • 13.3.11. QIAGEN Digital Insights launched ultra-fast NGS Analysis Able To Process a Whole Genome In 25 minutes For A USD 1 Cloud Computing Costs
  • 13.3.12. UK Set to Boost Genomics Expertise Through a Landmark Partnership with Thailand
  • 13.3.13. Complete Genomics Launches Full Sequencing Platforms at Biotech Showcase 2023
  • 13.3.14. Illumina Expands Collaboration with Janssen to Advance Molecular Residual Disease Cancer Test
  • 13.3.15. Agilent Acquires Avida Biomed, Boosting Next-generation Sequencing for Cancer Research
  • 13.3.16. Element Biosciences Unveils New DNA Sequencing Instrument, Chemistry

Companies Mentioned

• 1. 10x Genomics, Inc.
• 2. Abbott Laboratories
• 3. AbbVie Inc.
• 4. Agilent Technologies, Inc.
• 5. Azenta, Inc.
• 6. Becton, Dickinson and Company
• 7. BGI Genomics Co., Ltd.
• 8. Bio-Rad Laboratories, Inc.
• 9. BioChain Institute Inc.
• 10. Charles River Laboratories International, Inc.
• 11. Danaher Corporation
• 12. Dante Labs Inc.
• 13. Eppendorf SE
• 14. Eurofins Scientific SE
• 15. F. Hoffmann-La Roche Ltd.
• 16. Genomics England
• 17. Genscript Biotech Corporation
• 18. Illumina, Inc.
• 19. Johnson & Johnson Services, Inc.
• 20. Konica Minolta, Inc.
• 21. Laboratory Corporation of America Holdings
• 22. Macrogen Inc.
• 23. Merck KGaA
• 24. Novartis AG
• 25. Novogene Co, Ltd.
• 26. Oxford Nanopore Technologies PLC
• 27. Pacific Biosciences of California, Inc.
• 28. PerkinElmer, Inc.
• 29. QIAGEN N.V.
• 30. Sartorius AG
• 31. Shimadzu Corporation
• 32. SOPHiA GENETICS SA
• 33. Thermo Fisher Scientific Inc.
• 34. Twist Bioscience Corporation
• 35. Veritas Genetics Inc. by LetsGetChecked